Nerandomilast
As of the edition of 20 October 2026, Nerandomilast is a small molecule: marketed, first approved in 2025 (US); acts on PDE4B; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Jascayd
- First approved
- 7 October 2025 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Boehringer Ingelheim
- Registered trials
- 37, 0 stopped early
- Disease areas
- Lungs and airways; Skin and connective tissue; Bones, joints and muscles; Digestive system; Nervous system; Pregnancy and women's health
US protection
US protection ends in 2032.
The last listed US exclusivity ends in 2032. The application that gives this date is held by Boehringer Ingelheim.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product10 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 10 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Nerandomilast.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE4B | 3',5'-cyclic-AMP phosphodiesterase 4B | Q07343 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 23 | 23 | 0 | 0 |
| Phase 2 | 3 | 2 | 1 | 0 |
| Phase 3 | 9 | 2 | 7 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 37 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Originator and Lead sponsor of trials | 2012 to now |